Collecting Plasma Samples from Adults with Squamous Cell Carcinoma of the Head and Neck Receiving Targeted Therapies

What this Trial Is About

This research focuses on patients with squamous cell carcinoma of the head and neck who are treated with molecular targeted therapies. The study aims to collect plasma samples to explore biomarkers that might help predict how well treatments like cetuximab or other targeted agents work or if resistance to these treatments develops. This observational effort is sponsored by Cliniques universitaires Saint-Luc- Universit Catholique de Louvain. Participants are grouped based on their treatment type those receiving radiation therapy combined with cetuximab, those treated with cetuximab and chemotherapy, and those involved in clinical studies using other molecular targeted agents. Plasma samples will be collected at the start of treatment, throughout the treatment period at each radiological evaluation, and at disease progression. During the study, researchers will prospectively store plasma samples for at least one year after collection to analyze potential biomarkers. Participants will provide blood samples at multiple points, and the research team will monitor treatment progress through regular radiological assessments. The total duration of participation varies depending on the treatment and follow-up schedules.

Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients